Mylan N.V., MYL is in the exchange NASDAQ and its industry is Drugs – Generic in the sector of Healthcare. Based in USA, Mylan N.V., MYL has a market cap of 19295.71. Since its IPO date on the 12/18/1987, Mylan N.V., MYL performance year to date is -33.31%. Today Mylan N.V., MYL has gained -0.50%, with a current price of 35.88.
Ownership of the company is 0.20% for insider ownership while institutional ownership is 64.90%. The management of the company have seen the company have a payout ratio of 0.00%. Return of assets are at 0.90%, with return on investment at 8.20%.
In terms of debt levels and profit levels, Mylan N.V., MYL is seeing a long-term debt/equity of 0.96. While Total debt/equity is 1.34. With a profit margin of 2.50%, this is combined with a gross margin of 43.60%, and operating margin of 8.00%. Mylan N.V. ability to meet debt levels, with a current ratio of 0.8, while the quick ratio is 0.6.
For the last year Mylan N.V., MYL has seen a EPS growth of -31.50%. A performance for the year of -29.71%. The 52-week high is -35.36%, and the 52-week low is 6.79%. The average volume for Mylan N.V., MYL is 506027.
With a target price of 50.56, can Mylan N.V., MYL reach this target? Looking at the value indicators of Mylan N.V., MYL. Mylan N.V. has a P/E of 70.71 and a forward P/E of 6.7. Perhaps the more useful indicator than P/E, is PEG which has a value of 7.82. Mylan N.V. also has a P/S and a P/B of 1.87 and 1.6 respectively. For P/cash, Mylan N.V. has a value of 15.36, while it is 9.87 for P/free cash flow.
At the current price of 35.88, Mylan N.V. has a dividend yield of *TBA. We see a return on equity of 2.40%.
Looking more long-term Mylan N.V., is projected to get an EPS growth for the next five years of 9.04%. In the short-term an EPS growth of 13.35% in the next year is forecasted. This is after a EPS growth of -31.50% for this year and for the last five years a 20.20% growth has been seen.